Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 8.6% on Wednesday . The company traded as low as GBX 6.46 and last traded at GBX 6.67. 1,777,210 shares were traded during mid-day trading, a decline of 51% from the average session volume of 3,656,646 shares. The stock had previously closed at GBX 7.30.
ImmuPharma Stock Down 2.4%
The firm has a 50 day moving average of GBX 7.07 and a two-hundred day moving average of GBX 8.05. The firm has a market capitalization of £35.03 million, a price-to-earnings ratio of -7.83 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Silver Is the New Oil—And the World’s Running Dry
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- What happened in Cyprus could be coming here
- Elon Musk’s $1 Quadrillion AI IPO
- [How To] Invest Pre-IPO In SpaceX With $100!
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
